Allos Therapeutics Appoints Paul L. Berns as President and CEO
10 3월 2006 - 10:00PM
PR Newswire (US)
WESTMINSTER, Colo., March 10 /PRNewswire-FirstCall/ -- Allos
Therapeutics, Inc. (NASDAQ:ALTH) announced today the appointment of
Paul L. Berns as the Company's President, Chief Executive Officer
and a member of the Board of Directors, effective immediately. Mr.
Berns was most recently President, Chief Executive Officer and a
member of the Board of Directors of Bone Care International, Inc.
Stephen J. Hoffman, M.D., Ph.D., Chairman of the Board, stated,
"Paul has an outstanding track record of leadership and
accomplishment in the pharmaceutical industry, and we believe he is
the ideal candidate to lead the Company's future growth efforts. On
behalf of the Board of Directors, I am pleased to welcome Paul to
the Allos team, and also thank Mike Hart for his service and
dedication to the Company over the past six years." "I am
enthusiastic about joining Allos," said Mr. Berns. "I believe the
Company's product portfolio has significant clinical and commercial
potential, and I look forward to working with my new colleagues in
creating value for patients, employees and shareholders alike." Mr.
Berns brings close to 15 years of pharmaceutical industry
experience to Allos. While leading Bone Care International, Inc.
from June 2002 until its acquisition by Genzyme, Corp. in July
2005, revenues increased nearly 14-fold, the company became
profitable and market capitalization increased from approximately
$40 million to a sale value of $719 million. Prior to joining Bone
Care International, Inc., Mr. Berns held senior management
positions at Abbott Laboratories, BASF Pharmaceuticals, and
Bristol-Myers Squibb Company. With Mr. Berns' appointment, Michael
E. Hart resigned his positions as the Company's President, Chief
Executive Officer and Chief Financial Officer, and David C. Clark,
the Company's Corporate Controller and Treasurer, was appointed to
serve as the Company's Principal Financial Officer until a
permanent Chief Financial Officer is appointed. About Allos
Therapeutics, Inc. Allos Therapeutics, Inc. (NASDAQ:ALTH) is a
biopharmaceutical company focused on developing and commercializing
innovative small molecule therapeutics for the treatment of cancer.
The Company's lead product candidate, EFAPROXYN(TM) (efaproxiral),
is a synthetic small molecule designed to sensitize hypoxic, or
oxygen-deprived, tumor tissue during radiation therapy. EFAPROXYN
is currently being evaluated as an adjunct to whole brain radiation
therapy in a pivotal Phase 3 trial in women with brain metastases
originating from breast cancer. The Company's other product
candidates are: PDX (pralatrexate), a small molecule
chemotherapeutic agent (DHFR inhibitor) currently under
investigation as both a single agent and in combination therapy
regimens in patients with non-small cell lung cancer and
Non-Hodgkin's lymphoma; and RH1, a small molecule chemotherapeutic
agent bioactivated by the enzyme DT-diaphorase currently under
evaluation in patients with advanced solid tumors. For more
information, please visit the Company's web site at:
http://www.allos.com/. DATASOURCE: Allos Therapeutics, Inc.
CONTACT: Jennifer Neiman, Manager, Corporate Communications of
Allos Therapeutics, Inc., +1-720-540-5227, Web site:
http://www.allos.com/
Copyright
Allos Therapeutics, Inc. (MM) (NASDAQ:ALTH)
과거 데이터 주식 차트
부터 6월(6) 2024 으로 7월(7) 2024
Allos Therapeutics, Inc. (MM) (NASDAQ:ALTH)
과거 데이터 주식 차트
부터 7월(7) 2023 으로 7월(7) 2024
Allos Therapeutics, Inc. (MM) (나스닥)의 실시간 뉴스: 최근 기사 0
More Allos Therapeutics (MM) News Articles